Mutations arising in HER-1 ECD domain III as a result of cetuximab therapy, already known to determine treatment resistance due to epitope loss despite antigen conservation in tumours, were thus explored through the combination of Kunkel mutagenesis33 and phage display. This evidence concerns the gene EGFR and neoplasm.